Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Dec 20, 2006

MorphoSys and Pfizer Three-Year Deal Extension Doubles Worth

  • MorphoSys reported a three-year extension on its collaboration with Pfizer that more than doubles its potential worth. Pfizer now has the option to begin new therapeutic antibody projects. MorphoSys states that currently the collaboration encompasses five active therapeutic antibody programs.

    The initial five-year therapeutic antibody agreement that was signed in 2003 has now been extended to 2011. The potential value for MorphoSys in research funding and developmental milestone payments increases to more than $100 million, not including royalties. The extension also calls for Pfizer to make a one-time payment.

    MorphoSys will continue to use its HuCAL GOLD library to generate therapeutic antibodies against multiple new targets from Pfizer. Pfizer will carry out the preclinical and clinical development and the subsequent marketing of resulting products.



Be sure to take the GEN Poll

Cancer vs. Zika: What Worries You Most?

While Zika continues to garner a lot of news coverage, a Mayo Clinic survey reveals that Americans believe the country’s most significant healthcare challenge is cancer. Compared to other diseases, does the possibility of developing cancer worry you the most?

More »